Cadrenal Therapeutics, Inc. Logo

Cadrenal Therapeutics, Inc.

Developing novel anticoagulant therapies for high-risk cardiovascular patients.

CVKD | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
822 A1A NORTH, 32082 PONTE VEDRA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel anticoagulant therapies to address critical gaps in cardiovascular care. The company's mission is to create safer and more effective treatments with greater predictability and control, thereby reducing the risks of both clotting and bleeding. Its clinical-stage pipeline includes two primary assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral Factor XIa inhibitor for acute hospital settings. Cadrenal targets underserved, high-risk patient populations, including those with end-stage kidney disease and atrial fibrillation, as well as patients with implanted cardiac devices, aiming to reshape the standards of care in anticoagulation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cadrenal Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cadrenal Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cadrenal Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Aspire Biopharma Holdings, Inc. Logo
Developing a nano-platform for rapid, sublingual delivery of reformulated medications.
United States of America ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.
United States of America ASMB
Assertio Holdings, Inc. Logo
Offers branded prescription drugs for neurology, pain, and CNS to US patients.
United States of America ASRT
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503
Astena Holdings Co., Ltd. Logo
Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.
Japan 8095
AstraZeneca PLC Logo
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
United Kingdom AZN
ASTRAZENECA PLC Logo
Biopharmaceutical firm developing medicines for oncology, rare diseases, and metabolic disorders.
United States of America AZN
Astria Therapeutics, Inc. Logo
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America ATXS
ATAI Life Sciences N.V. Logo
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America ATAI

Talk to a Data Expert

Have a question? We'll get back to you promptly.